Breakdown | |||
TTM | Dec 2024 | Dec 2023 | Dec 2022 |
---|---|---|---|
Income Statement | Total Revenue | ||
490.47M | 396.29M | 115.79M | 79.87M | Gross Profit |
371.59M | 302.70M | 79.83M | 58.68M | EBIT |
-21.81M | -116.07M | -29.50M | -60.19M | EBITDA |
-18.15M | -112.91M | -27.72M | -59.39M | Net Income Common Stockholders |
41.39M | -83.42M | -26.26M | -58.34M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||
924.73M | 914.30M | 149.31M | 163.14M | Total Assets |
1.12B | 1.05B | 196.29M | 211.73M | Total Debt |
0.00 | 1.29M | 2.93M | 1.96M | Net Debt |
-86.43M | -78.27M | -42.16M | -74.13M | Total Liabilities |
80.13M | 89.71M | 38.87M | 41.90M | Stockholders Equity |
1.04B | 964.80M | 157.43M | 169.84M |
Cash Flow | Free Cash Flow | ||
108.17M | 102.43M | -15.48M | -39.77M | Operating Cash Flow |
143.53M | 136.68M | -12.72M | -35.90M | Investing Cash Flow |
-757.26M | -757.57M | -17.77M | -90.59M | Financing Cash Flow |
4.65M | 655.84M | -502.00K | 151.67M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | $11.25B | 29.27 | 6.70% | 3.74% | -12.90% | -51.90% | |
69 Neutral | $9.54B | 138.48 | -7.70% | ― | 32.63% | -233.25% | |
69 Neutral | $15.08B | 389.86 | 4.47% | ― | 200.19% | ― | |
66 Neutral | $4.53B | ― | -14.77% | ― | 2.16% | -55.38% | |
65 Neutral | $22.48B | 37.32 | 7.85% | ― | -18.28% | -70.98% | |
60 Neutral | $5.11B | ― | -12.78% | ― | 65.85% | 7.92% | |
57 Neutral | $4.90B | 18.92 | -17.01% | 7.26% | 13.61% | -24.47% |
Astera Labs, Inc. conducted its 2025 Annual Stockholders Meeting on June 5, 2025, where 144,451,882 shares were voted. During the meeting, stockholders elected three Class I directors to the board and ratified PricewaterhouseCoopers LLP as the company’s independent auditor for the fiscal year ending December 31, 2025. These decisions are expected to influence the company’s governance and financial oversight positively.
The most recent analyst rating on (ALAB) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Astera Labs, Inc. stock, see the ALAB Stock Forecast page.